![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CHGB |
Gene summary for CHGB |
![]() |
Gene information | Species | Human | Gene symbol | CHGB | Gene ID | 1114 |
Gene name | chromogranin B | |
Gene Alias | SCG1 | |
Cytomap | 20p12.3 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | P05060 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1114 | CHGB | HCC1_Meng | Human | Liver | HCC | 1.79e-04 | -4.13e-02 | 0.0246 |
1114 | CHGB | S014 | Human | Liver | HCC | 1.67e-08 | 1.69e+00 | 0.2254 |
1114 | CHGB | S015 | Human | Liver | HCC | 5.60e-16 | 1.87e+00 | 0.2375 |
1114 | CHGB | S016 | Human | Liver | HCC | 2.01e-23 | 2.21e+00 | 0.2243 |
1114 | CHGB | HTA12-15-2 | Human | Pancreas | PDAC | 1.60e-21 | 1.32e+00 | 0.2315 |
1114 | CHGB | HTA12-23-1 | Human | Pancreas | PDAC | 1.76e-04 | 8.39e-01 | 0.3405 |
1114 | CHGB | HTA12-25-1 | Human | Pancreas | PDAC | 1.02e-03 | 5.71e-01 | 0.313 |
1114 | CHGB | HTA12-26-1 | Human | Pancreas | PDAC | 1.38e-16 | 7.57e-01 | 0.3728 |
1114 | CHGB | HTA12-29-1 | Human | Pancreas | PDAC | 2.91e-31 | 7.47e-01 | 0.3722 |
1114 | CHGB | HTA12-9-1 | Human | Pancreas | PDAC | 2.21e-14 | 1.05e+00 | 0.1532 |
1114 | CHGB | HTA12-9-3 | Human | Pancreas | PDAC | 3.60e-11 | 1.28e+00 | 0.2045 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | ![]() |
Oral cavity | LP | ![]() |
Oral cavity | EOLP | ![]() |
Oral cavity | NEOLP | ![]() |
Esophagus | HGIN | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CHGB | SNV | Missense_Mutation | c.974N>A | p.Arg325Lys | p.R325K | P05060 | protein_coding | tolerated(0.13) | benign(0.259) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CHGB | SNV | Missense_Mutation | c.1006G>A | p.Glu336Lys | p.E336K | P05060 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
CHGB | SNV | Missense_Mutation | c.1687T>C | p.Phe563Leu | p.F563L | P05060 | protein_coding | deleterious(0.04) | possibly_damaging(0.571) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
CHGB | SNV | Missense_Mutation | c.1295N>T | p.Ser432Phe | p.S432F | P05060 | protein_coding | tolerated(0.6) | benign(0.123) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CHGB | SNV | Missense_Mutation | rs772514466 | c.1301N>A | p.Thr434Asn | p.T434N | P05060 | protein_coding | tolerated(0.61) | benign(0) | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
CHGB | SNV | Missense_Mutation | c.1311G>T | p.Glu437Asp | p.E437D | P05060 | protein_coding | tolerated(0.15) | benign(0.107) | TCGA-B6-A0RL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CHGB | SNV | Missense_Mutation | c.1730N>A | p.Ser577Tyr | p.S577Y | P05060 | protein_coding | tolerated(0.08) | possibly_damaging(0.686) | TCGA-C8-A12Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
CHGB | SNV | Missense_Mutation | c.883N>G | p.Gln295Glu | p.Q295E | P05060 | protein_coding | tolerated(0.28) | benign(0.027) | TCGA-E2-A14V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
CHGB | SNV | Missense_Mutation | c.2013N>C | p.Glu671Asp | p.E671D | P05060 | protein_coding | deleterious(0.01) | benign(0.396) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
CHGB | SNV | Missense_Mutation | c.1811T>C | p.Val604Ala | p.V604A | P05060 | protein_coding | deleterious(0.01) | probably_damaging(0.976) | TCGA-HG-A2PA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Taxol | PD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |